Exelixis

Exelixis ROE

The Return on Equity (ROE) of Exelixis (EXEL) as of Oct 28, 2026 is 36.21 %. In the previous year, Return on Equity (ROE) was 23.23 % — a change of 55.89% (higher).

ROE

36.21 %

YoY

55.89%

Last updated:

In 2025, Exelixis's return on equity (ROE) was 36.21 %, a 55.89% increase from the 23.23 % ROE in the previous year.

The Exelixis ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
53.60 USD
Jan 1, 2019
19.04 USD
Jan 1, 2020
5.95 USD
Jan 1, 2021
10.45 USD
Jan 1, 2022
7.33 USD
Jan 1, 2023
9.18 USD
Jan 1, 2024
23.23 USD
Jan 1, 2025
36.21 USD
The Exelixis ROE history
YEARROEYoY
36.21 %+55.89%
23.23 %+153.10%
9.18 %+25.28%
7.33 %-29.92%
10.45 %+75.71%
5.95 %-68.76%
19.04 %-64.48%
53.60 %-0.97%
54.12 %-168.84%
-78.62 %-148.31%
162.73 %-30.42%
233.86 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Exelixis Stock analysis

What does Exelixis do? Exelixis Inc. is a biopharmaceutical company that specializes in researching and developing drugs for various types of cancer. The company was founded in 1994 and is headquartered in Alameda, California. It has brought several drugs to the market over the years that have had a positive impact on thousands of patients. The company's founders, Corey Goodman, George Scangos, and John Walker, previously worked at Genentech and decided to start their own company to focus on cancer research and drug development. Exelixis Inc. has had numerous successes since its inception, including the development of Cabozantinib, a drug used to treat various types of cancer such as thyroid cancer, kidney cancer, and advanced prostate cancer. The company also has several drug candidates in clinical testing. Its business model revolves around researching and developing drugs that target proteins and signaling pathways overactivated in cancer cells. Exelixis Inc. often collaborates with other companies in the pharmaceutical industry to share development costs and risks. The company is divided into different divisions to treat various cancer types, including kidney, liver, thyroid, and lung cancer. One of its significant milestones was the approval of Cabozantinib by the FDA in 2012 for the treatment of advanced kidney and thyroid cancer. The drug has since been approved in other countries and has been successful in treating different types of cancer. Exelixis Inc. is dedicated to developing better and more effective cancer drugs to help patients. It works closely with doctors, researchers, and other pharmaceutical companies to constantly explore new approaches to combat cancer cells. In summary, Exelixis Inc. is a leading player in the research and development of drugs for various types of cancer. It has a track record of approved drugs and a pipeline of innovative drug candidates. The company's goal is to help cancer patients and contribute to improving people's health. Exelixis is one of the most popular companies on Eulerpool.

ROE Details

Decoding Exelixis's Return on Equity (ROE)

Exelixis's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Exelixis's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Exelixis's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Exelixis’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Exelixis stock

Return on Equity (ROE) of Exelixis is 36.21 % in 2025.

Return on Equity (ROE) of Exelixis changed from 23.23 % to 36.21 %, representing a 55.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Exelixis since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Exelixis with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Exelixis

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Exelixis